Al
Not verified

Alnylam Pharmaceuticals, Inc.

What we write about

BiotechnologyHealthMedicine - variousPharmaceuticalsWEB AND SOCIAL NETWORK
18/06/2025
Scienza
Biotechnology
Medicine - various
Cardiology
Health
Pharmaceuticals
Sanità
Labour market
Industria
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
1.00
09/06/2025
Scienza
Cardiology
Biotechnology
Pharmaceuticals
Health
Medicine - various
Labour market
Industria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
1.00
28/05/2025
Biotechnology
Pharmaceuticals
Health
Sanità
Eventi
WEB AND SOCIAL NETWORK
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
1.00
20/05/2025
Responsabilità sociale d'impresa
Industria
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Alnylam Issues 2024 Corporate Responsibility Report
1.00
05/05/2025
Eventi
WEB AND SOCIAL NETWORK
Biotechnology
Pharmaceuticals
Health
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
1.00
01/05/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Biotechnology
Food hygiene
Health
Pharmaceuticals
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
1.00
28/04/2025
Industria
Cardiology
Biotechnology
Food hygiene
Health
Sanità
Pharmaceuticals
Scienza
Medicine - various
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
1.00
17/04/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
Finance
stock market
Biotechnology
Pharmaceuticals
Health
Sanità
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
1.00

Contact details

Social Media

Followers
0
Compatibility
0